Discovery of Novel Na v 1.7-Selective Inhibitors with the 1 H -Indole-3-Propionamide Scaffold for Effective Pain Relief

Tingjun Hou, G. Wang, Hang Wu, Yingying Wang, Xiangying Liu, Shuijiao Peng, Wenxing Wang, Meijing Wu, Yifei Liu, Ercheng Wang, Zhe Wang, Lei Xu, Xiaojian Wang, Wei Yang, Haiyi Chen, Xi ZhouResearch 2025 · DOI

TL;DR

Researchers have discovered a novel class of Na<sub>v</sub>1.7 inhibitors, distinct from existing aryl sulfonamide drugs, that show significant promise for effective pain relief. This new compound, WN2-R, demonstrates potent analgesic effects across various pain models in mice, coupled with favorable safety and bioavailability, positioning it as a strong candidate for next-generation pain therapeutics.

What Problem Does This Paper Address?

The development of effective, non-addictive pain relievers is a major challenge in medicine. Voltage-gated sodium channel Na<sub>v</sub>1.7 is a key player in pain signaling and is considered a prime target for novel analgesics. While many Na<sub>v</sub>1.7 inhibitors have been developed, most share a common aryl sulfonamide scaffold. Despite showing strong in vitro activity and selectivity, these drugs have largely failed to demonstrate significant clinical efficacy, leading to a critical need for new structural classes of Na<sub>v</sub>1.7 inhibitors. This paper addresses this gap by exploring a novel chemical scaffold for Na<sub>v</sub>1.7 antagonism.

Methods

The study employed an integrated drug discovery strategy combining computational and experimental techniques. This included:

  • Structure-Based Virtual Screening (SBVS): A large library of over 1.7 million compounds was screened against the Na<sub>v</sub>1.7 voltage-sensing domain (VSDIV) pocket to identify potential hits.
  • Molecular Dynamics (MD) Simulations: Extensive MD simulations (up to 4 µs) were used to analyze the binding conformations of candidate inhibitors, predict preferred stereoisomers, and understand their interactions within the VSDIV pocket.
  • Computational Structural Optimization: Techniques were used to refine lead compounds and identify analogs with improved activity.
  • Chiral Separation and Analysis: The R and S enantiomers of the lead compound were synthesized and tested separately. Electronic Circular Dichroism (ECD) was used to confirm the chirality.
  • Site-Directed Mutagenesis: Specific amino acid residues in the Na<sub>v</sub>1.7 channel were mutated to alanine or glycine to experimentally verify the predicted binding site and the role of key residues.
  • Electrophysiology: Whole-cell patch-clamp recordings were used to measure the effect of the inhibitor on native Na<sup>+</sup>, K<sup>+</sup>, and Ca<sup>2+</sup> currents in dorsal root ganglia (DRG) neurons, and current-clamp recordings assessed its impact on neuronal excitability.
  • In Vivo Pain Models: The analgesic efficacy of the compound was evaluated in various mouse models, including acetic acid-induced writhing, formalin-induced inflammation, chronic inflammatory pain (CFA model), and spared nerve injury (SNI) for neuropathic pain.
  • Pharmacokinetic and Safety Studies: Acute toxicity tests and pharmacokinetic studies (oral and intravenous administration) were conducted to assess drug safety, bioavailability, and half-life.

Datasets

  • Compound Libraries: The study screened compounds from the ChemDiv and Specs databases.
  • Protein Structure: The crystal structure of Na<sub>v</sub>1.7-VSDIV-NaAb (PDB code: 5EK0) was used as a template for SBVS. Other PDB structures (e.g., 6J8J, 5EK0, 815G, 7W7F) were used for comparative structural analysis.
  • Animal Models: Standard mouse models for acute, chronic inflammatory, and neuropathic pain were utilized.

Key Insights and Ideas

  • Novel Scaffold for Na<sub>v</sub>1.7 Inhibition: The discovery of the 1H-indole-3-propionamide scaffold represents a significant departure from the prevalent aryl sulfonamide inhibitors, offering a new avenue for drug design.
  • Chirality Matters: The R-enantiomer (WN2-R) was found to be significantly more potent than the S-enantiomer, highlighting the importance of stereochemistry in Na<sub>v</sub>1.7 antagonism.
  • Unique Binding Mode: MD simulations and mutagenesis data suggest that WN2-R binds to the VSDIV pocket via a distinct mechanism, primarily driven by hydrophobic and cation-π interactions, rather than the polar interactions seen with aryl sulfonamides. This unique binding may contribute to its favorable properties.
  • Broad Analgesic Efficacy: WN2-R demonstrated effectiveness across a spectrum of pain types, including acute, chronic inflammatory, and neuropathic pain, outperforming a well-established positive control drug (PF-05089771) in some models, particularly neuropathic pain.
  • Favorable Drug-like Properties: The compound exhibits good subtype selectivity (minimal activity against other Na<sub>v</sub> subtypes), a positive safety profile in acute toxicity studies, and a promising oral bioavailability (20.29%).

Key Results

  • Potent Inhibition: WN2-R achieved an IC<sub>50</sub> of 24.7 ± 9.4 nM against Na<sub>v</sub>1.7.
  • Superior Efficacy: WN2-R showed significant analgesic effects in acetic acid writhing, formalin-induced pain, CFA-induced chronic pain, and SNI neuropathic pain models in mice. In the SNI model, WN2-R outperformed the positive control PF-05089771.
  • Selective Inhibition: WN2-R showed very low inhibitory rates against other Na<sub>v</sub> subtypes (e.g., Na<sub>v</sub>1.4 at 16.3%, Na<sub>v</sub>1.5 at 19.1%) at 1 µM.
  • High Bioavailability: Oral bioavailability (F) was determined to be 20.29%.
  • Reduced Neuronal Excitability: WN2-R effectively inhibited Na<sup>+</sup> currents and reduced the membrane excitability of DRG neurons.

Limitations and Future Work

  • Limitations:
    • The study acknowledges that while WN2-R showed good oral efficacy in some models, its performance in the formalin phase II was limited when administered orally, possibly due to bioavailability constraints in that specific model.
  • The paper mentions that the selectivity range of WN2-R might be more "reasonable" compared to extremely high selectivity, suggesting that a balance might be needed to avoid overlooking other signaling pathways.
  • The study still had "many limitations," and further in-depth explorations are needed.
  • Future Work:
    • Further optimization of the structure and properties of WN2-R is planned.
  • Additional research is needed to explore additional novel mechanisms and directions for next-generation analgesic drug development.
  • The authors suggest that the distinct binding mode and potential for avoiding high plasma protein binding (a pitfall of aryl sulfonamides) warrant further investigation.

Summary updated

Abstract

Na<sub>v</sub>1.7 is considered a promising target for developing next-generation analgesic drugs, given its critical role in human pain pathologies. Although most reported inhibitors with strong in vitro activity and high selectivity share the aryl sulfonamide scaffold, they failed to demonstrate marked clinical efficacy. Therefore, exploring new Na<sub>v</sub>1.7-selective antagonists is quite urgent to the development of next-generation analgesic drugs. Here, we report a highly effective 1<i>H</i>-indole-3-propionamide inhibitor, WN2, identified through an integrated drug discovery strategy. Notably, the structure of WN2 is quite different from previously reported aryl sulfonamide inhibitors. Molecular dynamics simulations and experimental findings reveal that the R configuration of WN2 (WN2-R) is the preferred form (IC<sub>50</sub> = 24.7 ± 9.4 nM) within the VSDIV pocket of Na<sub>v</sub>1.7. WN2-R exhibits impressive analgesic effects in acute and chronic inflammatory pain, as well as neuropathic pain models in mice. Additionally, it displays favorable subtype selectivity and positive drug safety in acute toxicity studies. Pharmacokinetic studies indicate that WN2-R has high bioavailability (<i>F</i> = 20.29%), highlighting its considerable potential for drug development. Our study establishes WN2-R as a novel Na<sub>v</sub>1.7-selective inhibitor with a unique structural scaffold, offering a promising candidate for the next generation of analgesic drugs.
BibTeX
@inproceedings{hou2025discovery,
  author = {Tingjun Hou and G. Wang and Hang Wu and Yingying Wang and Xiangying Liu and Shuijiao Peng and Wenxing Wang and Meijing Wu and Yifei Liu and Ercheng Wang and Zhe Wang and Lei Xu and Xiaojian Wang and Wei Yang and Haiyi Chen and Xi Zhou},
  title = {{Discovery of Novel Na <sub>v</sub> 1.7-Selective Inhibitors with the 1 <i>H</i> -Indole-3-Propionamide Scaffold for Effective Pain Relief}},
  booktitle = {Research},
  year = {2025},
  doi = {10.34133/research.0599},
}
Figure